Recombinant Endotoxin Testing Compendial Since 2025, LAL Stays

Introduction

For fifty years, one test protected patients from a silent threat. Bacterial endotoxin testing relied almost entirely on Limulus Amebocyte Lysate (LAL), an extract of horseshoe crab blood cells first validated by the FDA in 1987. Then, on July 26, 2024, USP's Microbiology Expert Committee approved Chapter <86>, a compendial pathway for recombinant reagents in bacterial endotoxins testing (BET).

The chapter was published for early adoption in November 2024 and became official on May 1, 2025, confirmed across USP's own announcement and independent trade coverage the chapter provides additional techniques for bacterial endotoxin testing using non-animal-derived reagents and became official in May 2025. Chapter <86> covers two non-animal-derived reagent classes: recombinant Factor C (rFC) and recombinant Cascade Reagent (rCR) the new chapter includes methods that use both recombinant cascade and recombinant Factor C reagents, giving manufacturers information to incorporate them into quality testing.

Crucially, USP was explicit that this is addition, not replacement. Manufacturers currently using LAL can continue to do so, and Chapter <86> has no impact on them.

So Why Hasn't the Industry Switched?

That single sentence explains most of the industry's inertia. Chapter <86> is permissive, not mandatory. LAL remains fully compendial under Chapter <85>. As one industry Q&A put it plainly:

"Companies initially hesitated because LAL was well-established, compendial, and backed by decades of data. Switching to recombinant methods required new equipment, training, and extensive validation without a clear regulatory framework." 

That hesitation has not fully lifted. While the majority of endotoxin testing is still carried out using traditional methods, the emergence of new recombinant reagents creates an opportunity to weigh the benefits of a shift. With 70 to 100 million endotoxin tests run globally each year, that installed base of LAL-validated methods represents enormous sunk cost market research suggests that between 70 million and 100 million endotoxin tests are carried out each year.

Barriers Still Slowing the Switch

The European Pharmacopoeia gap is a real complication for multinational manufacturers: EP 2.6.32 currently includes only Recombinant Factor C, not the newer Recombinant Cascade Reagent, so alignment between US and EU standards remains limited.

Recombinant endotoxin testing isn't the only compendial shift facing slow industry adoption — barrier technology is seeing the same lag under Annex 1.
→ Read: Isolator and RABS adoption curves in sterile fill-finish

What's Changing the Calculus

Momentum is building nonetheless. Despite decades of industry hesitation, USP recognition and ongoing research are expected to strengthen confidence in Chapter <86>, with recombinant technology projected to eventually rival or surpass LAL usage. Sustainability pressure on horseshoe crab populations, growing test volumes, and now a clear compendial framework are converging to make the business case easier to justify to quality leadership.

FAQs

Is LAL testing still compliant after May 2025?

Yes. USP confirmed that manufacturers using LAL can continue without any impact from Chapter <86>.

What is the official date of USP <86>?

It was published for early adoption in November 2024 and became official on May 1, 2025.

Is switching to recombinant reagents mandatory?

No. Chapter <86> is an additional, optional pathway alongside Chapter <85>.

What's the difference between rFC and rCR?

rFC uses a single recombinant enzyme; rCR replicates the full clotting cascade using multiple cloned enzymes, more closely mirroring LAL's biology.

Does Europe recognize the same recombinant methods as the US?

Not fully. EP 2.6.32 currently recognizes only rFC, not rCR, so global harmonization is incomplete.

This brief is for regulatory and quality-control awareness. Always confirm current chapter status against the live USP-NF and applicable regional pharmacopeias before making validation decisions.